ATOR-1017, a 4-1BB antibody developed for tumor-directed immunotherapy of cancer

被引：0
|
作者：
Werchau, Doreen [1 ]
Rosen, Anna [2 ]
Eriksson, Mia [1 ]
Jarnum, Sofia [1 ]
Furebring, Christina [1 ]
Smith, Karin Enell [1 ]
机构：
[1] Alligator Biosci AB, Lund, Sweden
[2] Alligator Biosci, Lund, Sweden
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P608
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer
    Lynch, David H.
    IMMUNOLOGICAL REVIEWS, 2008, 222 : 277 - 286
  • [32] A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation
    Lee, E.
    Chung, H.
    Lee, Y.
    Lee, E-J.
    Park, Y. B.
    Kim, Y.
    Park, J. Y.
    Ahn, S.
    Kim, J.
    Ahn, K. K.
    Park, K.
    Son, W.
    Yeom, D.
    Jung, J.
    Won, J.
    Oh, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S607 - S608
  • [33] A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) shows potent anti-tumor effect through tumor-directed T cell activation
    Song, Moo Young
    Lee, Eun-Jung
    Chung, Hyejin
    Lee, Yangsoon
    Park, Young Bong
    Jee, Min Hyeok
    Kim, KyeongBae
    Ju, Mikyeong
    Lee, Jun Kyung
    Choi, Byung Hyun
    Park, Ju Young
    Kim, DaeWon
    Kim, Junhwan
    Ahn, Sujin
    Ahn, Kyoung Kyu
    Park, Kyeongsu
    Jung, Uijung
    Son, Wonjun
    Eom, Jaehyun
    Kim, Eunjung
    Yeom, Donghoon
    Ahn, Jinhyung
    Song, Daehae
    Sung, Byungje
    You, Weon-kyoo
    Kim, Jong Gyun
    Oh, Se-Woong
    Jung, Jaeho
    CANCER RESEARCH, 2020, 80 (16)
  • [34] Immune biomarker profiling and safety evaluation response to 4-1BB antibody (Urelumab) in humanized 4-1BB mice
    Xiang, Jie
    Li, Dirui
    Yang, Hao
    Ng, Gary
    Shen, Yuelei
    CANCER RESEARCH, 2020, 80 (16)
  • [35] New Approaches to the Treatment of Pancreatic Cancer From Tumor-Directed Therapy to Immunotherapy
    Lowery, Maeve A.
    O'Reilly, Eileen M.
    BIODRUGS, 2011, 25 (04) : 207 - 216
  • [36] The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
    Kvarnhammar, Anne Mansson
    Veitonmaki, Niina
    Hagerbrand, Karin
    Dahlman, Anna
    Smith, Karin Enell
    Fritzell, Sara
    von Schantz, Laura
    Thagesson, Mia
    Werchau, Doreen
    Smedenfors, Kristine
    Johansson, Maria
    Rosen, Anna
    Aberg, Ida
    Winnerstam, Magnus
    Nyblom, Eva
    Barchan, Karin
    Furebring, Christina
    Norlen, Per
    Ellmark, Peter
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [37] ATG-101, A NOVEL PD-L1/4-1BB BISPECIFIC ANTIBODY, AUGMENTS ANTI-TUMOR IMMUNITY THROUGH IMMUNE CHECKPOINT INHIBITION AND PDL1-DIRECTED 4-1BB ACTIVATION
    Hui Yuwen
    Li, Tengteng
    Ren, Yijing
    Hoenemann, Dirk
    Mei, Jay
    Shan, Bo
    Hou, Bing
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A936 - A937
  • [38] The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
    Veitonmaki, Niina
    Thagesson, Mia
    Werchau, Doreen
    Hagerbrand, Karin
    Smedenfors, Kristine
    Mansson-Kvarnhammar, Anne
    Rosen, Anna
    Johansson, Maria
    Furebring, Christina
    Norlen, Per
    Ellmark, Peter
    CANCER RESEARCH, 2018, 78 (13)
  • [39] Discovery of a novel Claudin 6 X 4-1BB bispecific antibody with potent anti-tumor activity through conditional 4-1BB activation.
    Li, Jian
    Jiang, Wenqing
    Liu, Yan
    Wang, Zhengyi
    Chen, Xi
    Guo, Taylor B.
    CANCER RESEARCH, 2022, 82 (12)
  • [40] Inter-crosslinking peptide augments 4-1BB receptor clustering for cancer immunotherapy
    Lv, Gan-Tian
    Chen, Qing-Hua
    Wang, Man-Di
    Ye, Xin-Wei
    Liu, Yi-Xuan
    Liu, Shan
    Wang, Qian-Ting
    Lai, Wen-Jia
    Yang, Pei-Pei
    Wang, Hao
    NANO TODAY, 2023, 53
12345